// App-Quantinova.ai

EP1074 : A PHASE 2 STUDY OF THE LSD1 INHIBITOR IMG-7289 (BOMEDEMSTAT) FOR THE TREATMENT OF ADVANCED MYELOFIBROSIS

Researchers

Presenter

  • Harry Gill

Principal Investigators

  • Kristen Pettit

  • Terrence Bradley

  • Aaron Gerds

  • Maciej Tatarczuch

  • Jake Shortt

  • Natasha Curtin

  • James Rossetti

  • Kate Burbury

  • Adam Mead

  • Joachim Gthert

  • Stephen Koschmieder

  • Anna Halpern

  • Amber Jones

  • Jennifer Peppe

  • Georges Natsoulis

  • Willis Navarro

  • William Stevenson

  • Joanne Ewing

  • Ruben Mesa

  • Elisa Rumi

  • Nicola Vianetti

  • Monia Marchetti

  • Claire Harrison

  • Alessandro Vannucchi

  • Justin Watts

  • David Ross

  • Moshe Talpaz

  • Hugh Rienhoff

Medical Centers

  • Medical Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy

  • Azienda Opedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy

  • Weatherall Institute of Molecular Medicine and Oxford Cancer Centre, Oxford, United Kingdom

  • Sylvester Comprehensive Cancer Center,University of Miami,Miami,Stati Uniti

  • Dept. of Hematology, Peter MacCallum Cancer Center, Melbourne, Australia

  • Kolling Institute of Medical Research, Royal North Shore Hospital, Sydney, New South Wales, Australia

  • University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom

  • Center for Research and Innovation of Myeloproliferative Neoplasms,University of Florence,Florence,Italie

  • Haematology,Queen Mary Hospital,Hong Kong,China

  • Policlinico S.Orsola-Malpighi,Universitaria di Bologna,Bologna,Italy

  • Rheumatology Unit, Royal Adelaide Hospital, Adelaide, Australia

  • Rogel Cancer Center,University of Michigan,Ann Arbor,United States

  • UT Health San Antonio Cancer Center,University of Texas Health Science Center,San Antonio,Stati Uniti

  • Department of Clinical Haematology,Guy's &amp

  • Department of Global Health, University of Washington, Seattle, WA, United States

  • Taussig Cancer Institute,Cleveland Clinic,Cleveland,Vereinigte Staaten

  • Genetics,Imago BioSciences,South San Francisco,Stati Uniti

  • Rheumatology, Austin Health, Melbourne, Australia

  • Imago BioSciences, Inc.,South San Francisco,United States

  • School of Clinical Sciences, Monash University, Melbourne, Australia

  • Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA

  • Hematology,University of Kansas,Kansas City,United States

  • Hematology,Aachen University,Aachen,Germany

  • Guy's And St Thomas NHS Foundation Trust, London, United Kingdom

  • West German Cancer Center, University Hospital, Essen, Germany

Locations

  • Italy

  • United States

  • United Kingdom

  • Australia

  • China

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Myelofibrosis

Biomarkers

  • MPL proto-oncogene, thrombopoietin receptor

  • Calreticulin

  • Nuclear receptor subfamily 4 group A member 1

  • Lysine-specific histone demethylase 1A

  • Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Epsilon

Drug/Treatment

  • Ruxolitinib phosphate

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved